At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 6, 2026 at 06:31 ET
Biogen issued a preliminary earnings update for Q1 2026, expecting a $34 million charge for acquired in-process R&D and milestone expenses, impacting EPS by approximately $0.19 per share. This is a forward-looking estimate ahead of final results.
- Biogen expects a $34 million pre-tax charge for acquired in-process R&D, upfront, and milestone expenses in Q1 2026.
- The charge is expected to reduce both GAAP and non-GAAP diluted EPS by approximately $0.19 per share.
- Final results for Q1 2026 are not yet finalized and remain subject to closing procedures.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access